Intradermal tranexamic acid in the treatment of melasma: A prospective study of 20 Moroccan cases

Abstract

Background: The objective of this study was to evaluate the effectiveness and safety of tranexamic acid mesotherapy in the treatment of melasma in the Moroccan population. Materials and Methods: All the patients received an intradermal injection of tranexamic acid (5 mg/mL). No other local or general treatment was administered. The patients were kept under external photoprotection only. Pre- and post-treatment photographs were taken and analyzed with the Visioface® RD hardware. The evaluation was employed the MASI score. Results: All patients had a dark skin phototype. The average duration of melasma evolution was 3.67 years. The pre-treatment average MASI was 7.6. The post-therapeutic average MASI was 6. The Visioface® RD hardware estimated a 25% reduction in the surface area attained at month five. No serious side effects were reported. Conclusion: Tranexamic acid was proven to be an essential tool in treating melasma.